Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition

In this study we focused on the structure and expression of the HLA-E, F, and G class I complexes in placental tissue. Structural analysis included an examination of the peptides bound to soluble and membrane forms of the HLA-G complex isolated directly from placenta. An important distinction was observed from HLA-G bound peptides previously isolated from transfectant cells. Thus, the number of distinct moieties bound to placental-derived proteins was substantially lower than that bound to transfectant-derived HLA-G. Indeed, a single peptide species derived from a cytokine-related protein alone accounted for 15% of the molar ratio of HLA-G bound peptide. To further examine HLA-E and its potential to bind peptide, notably that derived from HLA-G, we combined new Abs to examine expression in placental tissues for all the known forms of the nonclassical class I molecules. Whereas membrane HLA-G was found in extravillous trophoblasts, soluble HLA-G was found in all placental trophoblasts, including villous cytotrophoblasts and syncitiotrophoblasts. Further, HLA-E was found in all cells that expressed either form of HLA-G, consistent with HLA-E being complexed with the HLA-G signal sequence-derived nonamer in these cells. Finally, using new reagents specific for HLA-F, a restricted pattern of expression was observed, primarily on extravillous trophoblasts that had invaded the maternal decidua. Comparative staining indicated that HLA-F was on the surface of these cells, defining them as the first to demonstrate surface expression of this Ag and the first cell type identified to express all three nonclassical HLA class I Ags simultaneously.

Development of a chronically catheterized maternal-fetal macaque model to study in utero mother-to-fetus HIV transmission: a preliminary report

The lack of a representative animal model that permits frequent in utero fetal blood sampling is a major limiting factor for the study of maternal-fetal HIV transmission. Therefore, we have developed a maternal-fetal virus infection model using chronically catheterized macaques to simultaneously study the time-course of viral infection in the mother and the response of the fetus to maternal HIV infection. Pregnant macaques were infected with 10(3) infectious units of HIV-2(287); every 3 days blood samples from both the mother and the fetus as well as amniotic fluid samples were collected. We found a varying degree of peak and time-to-peak virus load, virus-infected PBMCs, and free virus (determined by QC-RNA-PCR method) in maternal blood. Two of the three mothers with more than 10(8) copies of viral RNA/ml of plasma at peak viremia transmitted the virus to their fetuses at about 14 days post-infection. As observed with HIV-2(287) infected mothers, virus-infected fetuses also produced a rapid rate of CD4+ cell decline in utero.

Ni-Based SBA-15 Catalysts Modified with CeMnOx for CO2 Valorization via Dry Reforming of Methane: Effect of Composition on Modulating Activity and H2/CO Ratio

Dry reforming of methane with ratio CH4/CO2 = 1 is studied using supported Ni catalysts on SBA-15 modified by CeMnOx mixed oxides with different Ce/Mn ratios (0.25, 1 and 9). The obtained samples are characterized by wide-angle XRD, SAXS, N2 sorption, TPR-H2, TEM, UV-vis and Raman spectroscopies. The SBA-15 modification with CeMnOx decreases the sizes of NiO nanoparticles and enhances the NiO-support interaction. When Ce/Mn = 9, the NiO forms small particles on the surface of large CeO2 particles and/or interacts with CeO2, forming mixed phases. The best catalytic performance (at 650 °C, CH4 and CO2 conversions are 51 and 69%, respectively) is achieved over the Ni/CeMnOx/SBA-15 (9:1) catalyst. The peculiar CeMnOx composition (Ce/Mn = 9) also improves the catalyst stability: In a 24 h stability test, the CH4 conversion decreases by 18 rel.% as compared to a 30 rel.% decrease for unmodified catalyst. The enhanced catalytic stability of Ni/CeMnOx/SBA-15 (9:1) is attributed to the high concentration of reactive peroxo (O-) and superoxo (O2-) species that significantly lower the amount of coke in comparison with Ni-SBA-15 unmodified catalyst (weight loss of 2.7% vs. 42.2%). Ni-SBA-15 modified with equimolar Ce/Mn ratio or Mn excess is less performing. Ni/CeMnOx/SBA-15 (1:4) with the highest content of manganese shows the minimum conversions of reagents in the entire temperature range (X(CO2) = 4-36%, X(CH4) = 8-58%). This finding is possibly attributed to the presence of manganese oxide, which decorates the Ni particles due to its redistribution at the preparation stage.

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience

Introduction

Tyrosine kinase inhibitor (TKI) therapy has greatly improved the prognosis of patients with chronic myeloid leukemia (CML), improving the survival expectancy of patients with chronic phase (CP) CML to that of the general population. However, despite these advances, nearly 50% of patients with CP CML experience failure to respond to frontline therapy, and most fail to respond to the subsequent second-line TKI. Treatment guidelines for patients failing second-line therapy are lacking. This study aimed to determine the efficacy of TKIs as third-line therapy in a “real-world” clinical practice setting and identify factors favorably influencing the long-term outcomes of therapy.

Methods

We have retrospectively analyzed the medical records of 100 patients with CP CML.

Results

The median age of the patients was 51 (range, 21–88) years, and 36% of the patients were men. The median duration of the third-line TKI therapy was 22 (range, 1– 147) months. Overall, the rate of achieving complete cytogenetic response (CCyR) was 35%. Among the four patient groups with different levels of responses at baseline, the best results were achieved in the groups with any CyR at the baseline of third-line therapy. Thus, СCyR was reached in all 15 and 8/ 16 (50%) patients with partial cytogenetic response (PCyR) or minimal or minor CyR (mmCyR), respectively, whereas CCyR was detected only in 12/69 (17%) patients without any CyR at baseline (p < 0.001). Univariate regression analysis revealed that the factors negatively associated with CCyR achievement in thirdline TKI therapy were the absence of any CyR on first- or second-line TKI therapy (p < 0.001), absence of CHR prior to third-line TKI (p = 0.003), and absence of any CyR prior to third-line TKI (p < 0.001). During the median observation time from treatment initiation to the last visit [56 (4–180) months], 27% of cases progressed into accelerated phase or blast phase CML, and 32% of patients died.

Discussion

Progression-free survival (PFS) and overall survival (OS) were significantly higher in patients with CCyR on third-line than in the group without CCyR on third-line therapy. At the last visit, third-line TKI therapy was ongoing in 18% of patients, with a median time of treatment exposure of 58 (range, 6–140) months; 83% of these patients had stable and durable CCyR, suggesting that patients without CHR at baseline and without CCyR at least by 12 months on third-line TKI should be candidates for allogeneic stem cell transplantation, third-generation TKIs, or experimental therapies.

La2O3-CeO2-Supported Bimetallic Cu-Ni DRM Catalysts

The present work is focused on nickel catalysts supported on La2O3-CeO2 binary oxides without and with the addition of Cu to the active component for the dry reforming of methane (DRM). The catalysts are characterized using XRD, XRF, TPD-CO2, TPR-H2, and low-temperature N2 adsorption-desorption methods. This work shows the effect of different La:Ce ratios (1:1 and 9:1) and the Cu addition on the structural, acid base, and catalytic properties of Ni-containing systems. The binary LaCeOx oxide at a ratio of La:Ce = 1:1 is characterized by the formation of a solid solution with a fluorite structure, which is preserved upon the introduction of mono- or bimetallic particles. At La:Ce = 9:1, La2O3 segregation from the solid solution structure is observed, and the La excess determines the nature of the precursor of the active component, i.e., lanthanum nickelate. The catalysts based on LaCeOx (1:1) are prone to carbonization during 6 h spent on-stream with the formation of carbon nanotubes. The Cu addition facilitates the reduction of the Cu-Ni catalyst carbonization and increases the number of structural defects in the carbon deposition products. The lanthanum-enriched LaCeOx (9:1) support prevents the accumulation of carbon deposition products on the surface of CuNi/La2O3-CeO2 9:1, providing high DRM activity and an H2/CO ratio of 0.9.